AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00455403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Chloroquine Placebo tablet daily for 12 months followed by 12 months off drug with 1 visit at month 24
Study NCT01771406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: 8 weeks of Nebivolol treatment (5mg/day)
Study NCT01771406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: 8 weeks of CPAP treatment
Study NCT00110396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a FBS-free/HSA-free
Description: Pre-filled syringes 44mcg/injected subcutaneous 3x per week. Total study period is 96 weeks.
Study NCT00653627 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: Mycobacterium bovis Bacille Calmette-Guerin
Study NCT05669404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salt Restriction Group (SRG)
Description: Patients assigned to the SRG continued to consume their usual diet, but they had to restrict their sodium intake to 2,000 mg/ day. They were given a detailed booklet containing information about table salt, foods rich in sodium, and practical ways to decrease salt consumption. During each 45-min individual session, they received intensive counselling and training to increase adherence to salt restriction. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
Study NCT05669404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH Diet combined with salt restriction Group (DDG)
Description: Patients assigned to the DDG received a more extensive booklet, which which in addition to the information regarding salt restriction, contained detailed information about the DASH diet, and practical advice about how to start and stay on the assigned dietary pattern. In addition to the booklet, each patient received an individualized eating plan with six sample daily menus, incorporating the goals of the DASH diet. During the 45-min individual sessions, patients were intensively counselled and trained to increase adherence to salt restriction and the assigned dietary pattern. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
Study NCT05669404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet combined with salt restriction Group (MDG)
Description: Patients assigned to the MDG received a more extensive booklet, which which in addition to the information regarding salt restriction, contained detailed information about the MedDiet, and practical advice about how to start and stay on the assigned dietary pattern. In addition to the booklet, each patient received an individualized eating plan with six sample daily menus, incorporating the goals of the MedDiet diet. During the 45-min individual sessions, patients were intensively counselled and trained to increase adherence to salt restriction and the assigned dietary pattern. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
Study NCT03248687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up
Description: The intervention will be method of follow up.
Study NCT03248687 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow up
Description: The intervention will be method of follow up.
Study NCT01008566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV
Study NCT01008566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01008566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given orally
Study NCT01131455 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Concentrated Plasma
Description: Autologous blood products have created a growing interest for use in a number of orthopedic therapies. The healing effects of plasma are supported by growth factors released by platelets. These growth factors induce a healing process wherever they are applied. The Arthrex ACP System is a cost-effective method of concentrating growth factors for therapeutic use.
Study NCT01332344 — intervention group
Intervention type: DRUG
Intervention: Fluticasone propionate/salmeterol combination
Description: Asthma subjects newly prescribed fluticasone propionate/salmeterol combination
Study NCT01332344 — intervention group
Intervention type: DRUG
Intervention: Inhaled corticosteroids
Description: asthma subjects newly prescribed inhaled corticosteroids in clinical practice
Study NCT03466450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: Glasdegib (3 dose levels will be evaluated: 100mg QD, 150mg QD and 200mg QD, or 75-50mg) will be administered:~During concurrent phase concomitantly with radiation and Extended to the resting period (glasdegib will not be stopped in the 4 weeks of radiotherapy resting period).~During adjuvant therapy with Temozolomide Oral Capsule. Additional treatment with glasdegib beyond 6 sequential TMZ cycles will continue until progression, unacceptable toxicity, non-compliance, consent withdrawal and/or 2 years of glasdegib administration.
Study NCT03466450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide Oral Capsule
Description: During RT, patients will receive Temozolamide (TMZ). All patients will be given TMZ at 75 mg/m2~/d concurrently with RT for a maximum of 42 days. At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles.
Study NCT03238651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 Tablets.
Study NCT00581750 — intervention group
Intervention type: OTHER
Intervention: Tissue specimen
Description: Human tissues taken after the clinically indicated removal of these tissues from patients as part of their routine care.
Study NCT03859427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib
Description: Once weekly IV over 30 minutes on day 1, 8 and 15 of each 28 day cycle. The dose will be 20 mg/m2 on cycle 1 day 1 and 56 mg/m2 beginning with cycle 1 day 8 and thereafter. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent.
Study NCT02091167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation
Description: Direct currents are transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current is delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode is placed over F3 according to the 10-20 international system while the anode is placed over the contralateral F4 region. The currents flows continuously for 20 minutes with an intensity of 2 milliamperes.
Study NCT02091167 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: Direct currents are transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current is delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode is placed over F3 according to the 10-20 international system while the anode is placed over the contralateral F4 region. The currents flows continuously for 20 minutes with an intensity of 2 milliamperes.
Study NCT02090907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Study NCT02090907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00903838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pardoprunox
Description: 1.5 to 12 mg/day
Study NCT00903838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole
Description: 0.75-4.5 mg/day
Study NCT00704145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taxus Libertè™ paclitaxel drug-eluting stent
Description: device:Taxus Libertè™ (Boston Scientific,Natick,MS)assessed at different time points after implant
Study NCT01016834 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sumavel DosePro
Description: Needle free delivery system containing 0.5 mL of solution of 6 mg sumatriptan, subcutaneous administration
Study NCT01016834 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sumatriptan
Description: subcutaneous injection, 6 mg, per migraine attack, no more than two administrations within a 24 hr period
Study NCT05433883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleep surgery
Description: Thirty severe OSA patients (AHI>30, treatment group) receive comprehensive upper airway surgery with/without bariatric surgery and repeat postoperative assessment in polysomnography and aforementioned examinations 1 year later.
Study NCT05958979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes
Study NCT03859427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib
Description: Twice weekly IV over 10 minutes on day 1, 2, 8, 9, 15 and 16 of each 28 day cycle. The dose will be 20 mg/m2 on cycle 1 days 1 and 2 and 27 mg/m2 beginning with cycle 1 day 8 and thereafter. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent.
Study NCT03859427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Once daily orally 25 mg days 1 to 21 of each cycle. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent
Study NCT01259661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A longitudinal intervention
Description: In our longitudinal intervention study, all eligible subjects will undergo a physical examination by a physician to rule out obvious secondary causes of hypertension and contraindications to exercise. Randomization will be performed by random member generation. The exercise participants will attend three sessions per week at the facility during the study period. Training intensity is initially set at heart rate equivalent to 60% and progress to 80% of each subject's maximal heart rate reserve for 30 min/day with a frequency of 3 days/wk. Facility-based exercise sessions will consist of treadmill walking.
Study NCT01259661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A longitudinal intervention
Description: In our longitudinal intervention study, all eligible subjects will undergo a physical examination by a physician to rule out obvious secondary causes of hypertension and contraindications to exercise. Randomization will be performed by random member generation. The exercise participants will attend three sessions per week at the facility during the study period. Training intensity is initially set at heart rate equivalent to 60% and progress to 80% of each subject's maximal heart rate reserve for 30 min/day with a frequency of 3 days/wk. Facility-based exercise sessions will consist of treadmill walking.
Study NCT04519632 — intervention group
Intervention type: OTHER
Intervention: Qualitative study
Description: Qualitative interviews
Study NCT04089150 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiotherapy (SBRT)
Description: 40 Gray (Gy) in 5 fractions, 2-3 fractions per week over two weeks, 8 Gy per fraction
Study NCT04089150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFIRINOX
Description: * Day 1: oxaliplatin 85mg/m2 + irinotecan 150mg/m2 + leucovorin 50mg~* 5-FU 2400mg/m2 continuous IV infusion, 46 hour continuous infusion~* 14-day cycle, 6 cycles
Study NCT04089150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: * Day 1: oxaliplatin 85mg/m2 + irinotecan 150mg/m2 + leucovorin 50mg~* 5-FU 2400mg/m2 continuous IV infusion, 46 hour continuous infusion~* 14-day cycle, 6 cycles
Study NCT04089150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + Nab-paclitaxel
Description: * Day 1, Day 8 and Day 15 gemcitabine 1000mg/m2 + nab-paclitaxel 125mg/m2~* 28-day cycle, 3 cycles
Study NCT04089150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Nab-paclitaxel
Description: * Day 1, Day 8 and Day 15 gemcitabine 1000mg/m2 + nab-paclitaxel 125mg/m2~* 28-day cycle, 3 cycles
Study NCT04089150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + Capecitabine
Description: * Week 1, 2 and 3, qw: 1000 mg/m2 gemcitabine~* 21 days continuous: 830 mg/m2 oral capecitabine + 7 days rest~* 28-day cycle, 3 cycles
Study NCT04089150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Capecitabine
Description: * Week 1, 2 and 3, qw: 1000 mg/m2 gemcitabine~* 21 days continuous: 830 mg/m2 oral capecitabine + 7 days rest~* 28-day cycle, 3 cycles
Study NCT04089150 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatoduodenectomy (Whipple procedure)
Description: R0 resection. When the tumour is within the head of the pancreas, a standard Whipple's procedure and level 2/3 dissection with modification to obtain margin clearance will be offered. For lesions in the tail, a standard modular resection will be offered.
Study NCT04089150 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatoduodenectomy (Whipple procedure)
Description: R0 resection. When the tumour is within the head of the pancreas, a standard Whipple's procedure and level 2/3 dissection with modification to obtain margin clearance will be offered. For lesions in the tail, a standard modular resection will be offered.
Study NCT04924738 — intervention group
Intervention type: BEHAVIORAL
Intervention: Monitoring and lifestyle
Description: Dietary and lifestyle modification recommended for pregnant women with hyperglycemia detected in pregnancy.
Study NCT03253666 — intervention group
Intervention type: OTHER
Intervention: Nutrient Intake
Description: Dietary nutrient intake (such as folate) and supplemental nutrient intake (such as folic acid)
Study NCT02556710 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 mL injection of AMPION™
Description: 4 mL Injection of Ampion
Study NCT02556710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 4 mL injection of Placebo
Description: 4 mL Injection of Placebo
Study NCT03985553 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parenting Self-Management Program
Study NCT03142295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: urine transfusion
Description: Two transfusions of 100 ml of urine within 5 days by transurethral catheterization after an antibiotic free interval of 3 days.
Study NCT02929576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be administered as four 40-mg capsules once daily (160 mg/day).
Study NCT02929576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02929576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (90 mg/m2) will be administered by constant-rate intravenous infusion of ≤ 1 hour once weekly for 16 weeks. Dose reductions or alterations to the schedule are allowed to maintain patient safety.
Study NCT02929576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (90 mg/m2) will be administered by constant-rate intravenous infusion of ≤ 1 hour once weekly for 16 weeks. Dose reductions or alterations to the schedule are allowed to maintain patient safety.
Study NCT00991302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAP-IT
Description: Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)
Study NCT04124549 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual care with sham intervention
Description: Patients in the control group received usual care and were advised to do sham exercise such as stretch legs and arms about 15 minutes during the first 2 HD hours.
Study NCT04124549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intradialytic Combined Exercise
Description: Each session consisted of a 5-minute warm-up, cool-down and 30-minute cycling at a Rating of Perceived Exertion (RPE) of 12-14. The machine has two exercise types including aerobic exercise and resistance exercise. Patients were asked to perform aerobic exercise 20-min and resistance exercise 10-min in the first stage. Every four weeks is divided into a stage. And the time of aerobic exercise and resistance exercise were personally adjusted per stage to maintain the personalized target RPE. In the following stages, aerobic exercise was continued 15-min for the second stage, 10-min for the third and the forth stage, 15-min for the fifth stage and 20-min for the last stage. And the time for resistance exercise was adjusted for the total exercise time. The resistance of exercise also progressive increased in order to adapt the target RPE. It was accessible to patients of different ages, gender, cultures and ethnicities.
Study NCT04516161 — intervention group
Intervention type: DRUG
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Receiving Ra-223 either alone or in combination with other cancer therapies at any time after diagnosis of mCRPC
Study NCT03370341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active anodal tDCS
Description: active anodal tDCS with behavioral tasks to assess IA
Study NCT03370341 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: active anodal tDCS
Description: active anodal tDCS with behavioral tasks to assess IA
Study NCT03370341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS
Description: sham tDCS with behavioral tasks to assess IA
Study NCT03370341 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: sham tDCS with behavioral tasks to assess IA
Study NCT01636141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OLT1177 Gel
Description: OLT1177 Gel - 3% or 5% administered topically to a defined area of one knee
Study NCT03859427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Once daily orally or by IV 40 mg days 1, 8 and 15 of each cycle. Also day 22 of cycles 1 to 9. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent
Study NCT02696343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NTrainer
Description: pulsed orocutaneous stimulation paired with tube feedings
Study NCT01636141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Study NCT02904252 — intervention group
Intervention type: OTHER
Intervention: Transient elastography
Description: Transient elastography (TE) is an ultrasound-based device used for measuring the degree of liver stiffness. A transducer probe is used to create mild amplitude and low frequency vibrations (50 Hz) that transmitted through the liver tissue. This results in an elastic shear wave that propagates through the underlying liver tissue. The probe then utilizes pulse-echo ultrasound to follow the propagation of the shear wave and to measure its velocity. The velocity of the wave is directly related to tissue stiffness which correlates with fibrosis. The sensitivity and the specificity of TE is between 68%-88% and between 66%-100%, respectively for the detection of significant liver fibrosis (METAVIR score F>2).
Study NCT01099124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES
Description: polyethylene glycol rh recombinant endostatin
Study NCT01072487 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capnography
Description: Monitoring of the capnography curve for early detection of apnea
Study NCT05905185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich fraction vitamin E (TRF)
Description: The 50 mg of vitamin E isomers in the TRF included 17.1 mg of α-tocopherol ,18.28 mg of α- tocotrienol, 2.02 mg of β-tocotrienol, 22.3 mg of γ-tocotrienol and 7.4 mg of δ-tocotrienol.
Study NCT05905185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50mg of Placebo
Study NCT04866394 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients will be planned with the aim of delivering 30 Gy in 5 fractions.
Study NCT02381392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accuvein AV400
Description: This device is FDA approved for assistance with intravenous access. It has been shown to cause no harm to patients. The device utilizes infrared technology to provide a visible map of the subject's blood vessels where the light is shone.
Study NCT01534390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-line microfilter (Supor IV Filter; Pall Corporation, Port Washington, New York)
Description: use of in-line microfilters with a pore size of 0,2 mcm and 1,2 mcm (only if parenteral nutrition is administered) at all intravenous accesses
Study NCT02696343 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM blind pacifier
Description: regular green Soothie pacifier paired with tube feedings
Study NCT01808066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Groundskeeper
Description: Groundskeeper is a product developed for helping players develop skills to increase focus and attention. The game is played on small Sifteo Cubes that have sensors that react to you and each other. There are new games that might help children with ADHD and Autism learn to better focus and keep attention on a task.
Study NCT01483703 — intervention group
Intervention type: DEVICE
Intervention: Laser Speckle Imaging
Description: Laser Speckle Imaging of Critical Care Neonates